Publication date: Dec 01, 2024
Evidence shows that diabetes raises the probability of contracting COVID-19 and associated complications. We hypothesize that metformin, being pleiotropic, may improve COVID-19 in diabetics. A retrospective cohort study was conducted with 421 COVID-19 patients with diabetes, hospitalized between 1st April 2020 and 31st March 2022 in a tertiary-care hospital. Patients with metformin or its combination constituted the study cohort (SC; n = 221), while other antidiabetics constituted the reference cohort (RC; n = 200). SC and RC were matched for mean age +/- SD (SC: 53. 3 +/- 5. 7 vs. RC: 54. 3 +/- 8. 2 years). The mean length of hospitalization (days) was significantly shorter in SC (9. 0 +/- 5. 7) than in RC (12. 7 +/- 6) (p
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Metformin |
disease | MESH | COVID-19 |
disease | MESH | diabetes mellitus |
disease | IDO | facility |
disease | MESH | complications |
disease | MESH | Diabetes Mellitus Type 2 |